Background This review describes the research and development process of
gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat …

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

Background Gantenerumab is a fully human monoclonal antibody that binds aggregated
amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the …

Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully
human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor …

Alzheimer's disease (AD) is a progressive neurodegenerative disease that often grows in
middle-aged and elderly people with the gradual loss of cognitive ability. Presently, there is …

Abstract Introduction The LipiDiDiet trial investigates the effects of the specific multinutrient
combination Fortasyn Connect on cognition and related measures in prodromal Alzheimer's …

Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a complex
pathogenesis. Senile plaques composed of the amyloid-β (Aβ) peptide in the brain are the …

After intense scientific exploration and more than a decade of failed trials, Alzheimer's
disease (AD) remains a fatal global epidemic. A traditional research and drug development …

Background: The characterizing symptom of Alzheimer disease (AD) is cognitive
deterioration. While much recent work has focused on defining AD as a biological construct …